Serina Therapeutics, Inc.SERNYSE
LOADING
|||
EV to Sales: Premium Valuation
Trending higher, above historical average, strong compound growth.
Left:
||||
Enterprise value to sales ratio
Latest
597.58
↑ 151% above average
Average (8y)
238.53
Historical baseline
Range
High:1183.64
Low:17.95
CAGR
+33.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 597.58 | +1589.6% |
| 2023 | 35.37 | -54.4% |
| 2022 | 77.49 | +331.7% |
| 2021 | 17.95 | -98.5% |
| 2020 | 1183.64 | +2886.4% |
| 2019 | 39.63 | -44.3% |
| 2018 | 71.14 | +9.5% |
| 2017 | 64.98 | +10.1% |
| 2016 | 59.03 | - |